Australian Clinical Labs (ASX:ACL) announced its financial results for the first half of fiscal year 2026, showcasing a strategic shift toward "earnings quality" despite a challenging broader market.
While total revenue saw a slight dip of 1.0% to $365.4 million, the company successfully expanded its underlying margins and delivered growth in key profit metrics.
The company's focus on operational efficiency is evident in its underlying EBIT, which grew by 2.4% to $28 million.
The performance was bolstered by a 30-basis-point margin expansion, reaching 7.7%.
Management attributed these gains to the strategic closure of loss-making Approved Collection Centres, improved workforce productivity, and the integration of AI-enabled technologies within their laboratories.
While the broader Medicare Benefits Schedule outlays grew by 1.8%, ACL’s outlays contracted by 1.4%, reflecting a deliberate pivot away from unprofitable volume toward higher-margin business.
The bottom line remained robust, with underlying NPAT rising 8.9% to $13.2 million and underlying earnings per share jumping 12.8% to 6.7 cents.
However, statutory figures told a different story; Statutory NPAT fell 51.7% to $5.7 million, and free cash flow decreased by 21.4%, largely due to non-recurring items and a $6.2 million AIC settlement payment.